We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GAO: FDA’s Monitoring of Early Abortion Drug Does Not Raise Safety Concerns
GAO: FDA’s Monitoring of Early Abortion Drug Does Not Raise Safety Concerns
The Government Accountability Office reviewed the FDA’s relabeling of Mifeprex — an early abortion pill covered by a risk evaluation and mitigation strategy — and concluded that the agency’s monitoring did not raise significant safety concerns.